Medtronic PLC $MDT Shares Sold by St. James Investment Company LLC

St. James Investment Company LLC reduced its holdings in shares of Medtronic PLC (NYSE:MDT) by 2.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 308,461 shares of the medical technology company’s stock after selling 6,324 shares during the period. Medtronic makes up 4.6% of St. James Investment Company LLC’s holdings, making the stock its 8th largest position. St. James Investment Company LLC’s holdings in Medtronic were worth $29,378,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Turtle Creek Wealth Advisors LLC increased its holdings in shares of Medtronic by 44.7% during the third quarter. Turtle Creek Wealth Advisors LLC now owns 4,886 shares of the medical technology company’s stock valued at $465,000 after acquiring an additional 1,509 shares in the last quarter. Verdence Capital Advisors LLC grew its position in Medtronic by 48.0% during the 3rd quarter. Verdence Capital Advisors LLC now owns 43,500 shares of the medical technology company’s stock worth $4,095,000 after purchasing an additional 14,104 shares during the last quarter. Courier Capital LLC increased its stake in Medtronic by 10.5% during the 3rd quarter. Courier Capital LLC now owns 46,246 shares of the medical technology company’s stock valued at $4,404,000 after purchasing an additional 4,411 shares in the last quarter. Allstate Corp increased its stake in Medtronic by 1,743.2% during the 3rd quarter. Allstate Corp now owns 46,614 shares of the medical technology company’s stock valued at $4,440,000 after purchasing an additional 44,085 shares in the last quarter. Finally, NorthCrest Asset Manangement LLC raised its holdings in shares of Medtronic by 6.5% in the third quarter. NorthCrest Asset Manangement LLC now owns 107,694 shares of the medical technology company’s stock worth $10,590,000 after buying an additional 6,573 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Stock Down 2.2%

MDT opened at $96.82 on Tuesday. The company has a fifty day moving average of $99.08 and a two-hundred day moving average of $94.99. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. Medtronic PLC has a fifty-two week low of $79.55 and a fifty-two week high of $106.33. The stock has a market capitalization of $124.12 billion, a price-to-earnings ratio of 26.10, a PEG ratio of 2.55 and a beta of 0.71.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. The firm had revenue of $8.96 billion for the quarter, compared to analysts’ expectations of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The company’s quarterly revenue was up 6.6% on a year-over-year basis. During the same period last year, the firm earned $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, research analysts expect that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were issued a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend was Friday, December 26th. Medtronic’s payout ratio is presently 76.55%.

Analysts Set New Price Targets

MDT has been the topic of several research reports. Cowen reissued a “buy” rating on shares of Medtronic in a research report on Friday, November 14th. UBS Group boosted their price target on Medtronic from $95.00 to $102.00 and gave the company a “neutral” rating in a research note on Wednesday, November 19th. Wells Fargo & Company lifted their target price on Medtronic from $100.00 to $114.00 and gave the stock an “overweight” rating in a report on Wednesday, November 19th. Morgan Stanley upped their price objective on shares of Medtronic from $107.00 to $117.00 and gave the company an “overweight” rating in a report on Wednesday, November 19th. Finally, Daiwa Capital Markets raised their target price on shares of Medtronic from $104.00 to $117.00 and gave the stock a “buy” rating in a report on Tuesday, November 25th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eleven have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $110.28.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).